Work

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

Year: 2008

Type: article

Study design: Clinical Trial

Source: Anti-Cancer Drugs

DOI: 10.1097/cad.0b013e3282f077b3

Authors: D. Ross Camidge, S. Gail Eckhardt, Lia Gore, Cindy L. O'Bryant, Stephen Leong, Michelle Basche, Scott N. Holden, Luna Musib, John Baldwin, Christelle Darstein, Donald Thornton, Richard S. Finn, Carolyn D. Britten

Institutions: University of Colorado Cancer Center, Livestrong Foundation, University of Colorado Denver, Eli Lilly (United States), University of California, Los Angeles

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Stop Cancer, Eli Lilly and Company, University of Cambridge, National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2042942970

FWCI: 2.287

Cites: 18

Cited by: 27

Related to: 10